Biology of adipose tissue

Joslin's Diabetes Mellitus: Fourteenth Edition

Volumn , Issue , 2011, Pages 207-226

  Collins, Sheila ^a   Ahima, Rexford S ^b,e   Kahn, Barbara B ^c,d  

^a CIIT CENTERS FOR HEALTH RESEARCH   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84971016406     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (271)

1. Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001;286:1195-1200.
2. Reitman ML, Arioglu E, Gavrilova O, et al. Lipoatrophy revisited. Trends Endocrinol Metab 2000;11:410-416.
3. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-432.
4. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000;11:327-332.
5. Hull D, Segall MM. Distinction of brown from white adipose tissue. Nature 1966;212:469-472.
6. Fawcett DW. A comparison of the histological organization and histochemical reactions of brown fat and ordinary fat. . Morphol 1952;90:363-372.
7. Giordano A, Morroni M, Santone G, et al. Tyrosine hydroxylase, neuropeptide Y, substance P, calcitonin gene-related peptide and vasoactive intestinal peptide in nerves of rat periovarian adipose tissue: an immunohistochemical and ultrastructural investigation. . Neurocytol 1996;25:125-136.
8. Bartness TJ, Bamshad M. Innervation of mammalian white adipose tissue: implications for the regulation of total body fat. Am J Physiol 1998;275: R1399-1411.
9. Cinti S. The adipose organ. Milan, Italy: Editrice Kurtis, 1999.
10. Cushman SW. Structure-function relationships in the adipose cell, I: ultrastructure of the isolated adipose cell. . Cell Biol 1970;46:326-341.
11. Cushman SW. Structure-function relationships in the adipose cell, II: pinocytosis and factors influencing its activity in the isolated adipose cell. . Cell Biol 1970;6:342-353.
12. Greenberg AS, Egan JJ, Wek SA, et al. Perilipin, a major hormonally regulated adipocyte-specific phosphoprotein associated with the periphery of lipid storage droplets. . Biol Chem 1990;11341-11346.
13. Bjorntorp P. The regulation of adipose tissue distribution in humans. Int J Obes Relat Metab Disord 1996;20:291-302.
14. Montague CT, O'Rahilly S. The perils of portliness: causes and consequences of visceral adiposity. Diabetes 2000;49:883-888.
15. Stern JS, Greenwood MR. A review of development of adipose cellularity in man and animals. Fed Proc 1974;33:1952-1955.
16. Bjorntorp P. Size, number and function of adipose tissue cells in human obesity. Horm Metab Res 1974[Suppl 4]:77-83.
17. Faust IM, Johnson PR, Stern JS, et al. Diet-induced adipocyte number increase in adult rats: a new model of obesity. Am J Physiol 1978;235:E279-E286.
18. Carpentier J, Perrelet A, Orci, L. Morphological changes of the adipose cell plasma membrane during lipolysis. . Cell Biol 1977;72:104-117.
19. Napolitano L, Gagne H. Lipid-depleted white adipose cells: an electron microscope study. Anat Rec 1963;147:273-278.
20. Belfrage E. Vasodilatation and modulation of vasoconstriction in canine subcutaneous adipose tissue caused by activation of beta-adrenoceptors. Acta Physiol Scand 1978;102:459-468.
21. Fukumura D, Ushiyama A, Duda DG, et al. Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesis. Circ Res 2003;93:88e-97.
22. Rupnick MA, Panigraphy D, Zhang CY, et al. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci U S A 2002;99:10730-10735.
23. Brakenhielm E, Cao R, Gao B, et al. Angiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in mice. Circ Res 2004;94:1579-1588.
24. Miyazawa-Hoshimoto S, Takahashi K, Bujo H, et al. Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects. Diabetologia 2003;46:1483-1438.
25. Mick GJ, Wang X, McCormick K. White adipocyte vascular endothelial growth factor regulation by insulin. Endocrinology 2002;143:948-953.
26. Kolonin MG, Saha PK, Chan L, et al. Reversal of obesity by targeted ablation of adipose tissue. Nat Med 2004;10:625-632.
27. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. . Clin Invest 2003;112:1785-1788.
28. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophase accumulation in adipose tissue. . Clin Invest 2003;112:1796-1808.
29. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. . Clin Invest 2003;112:1821-1830.
30. Kim JK, Kim YJ, Fillmore JJ, et al. Prevention of fat-induced insulin resistance by salicylate. . Clin Invest 2001;108:437-446.
31. Lindberg O. Brown adipose tissue. New York: American Elsevier Publishing, 1970.
32. Smith R. Thermogenic activity of the hibernating gland in the cold-acclimated rat. Physiologist 1961;4:113.
33. Ball E, Jungas R. On the action of hormones which accelerate the rate of oxygen consumption and fatty acid release in rat adipose tissue in vitro. Proc Natl Acad Sci U S A 1961;47:932-941.
34. Bukowiecki L, Collet A, Follea N, et al. Brown adipose tissue hyperplasia: a fundamental mechanism of adaptation to a cold and hyperphagia. Am J Physiol 1982;242:E353-E359.
35. Góloën A, Collet AJ, Bukowiecki LJ. Role of sympathetic innervation in brown adipocyte proliferation. Am J Physiol 1992;263:R1176-R1181.
36. Girardier L. The regulation of the biological furnace of warm blooded animals. Experientia 1977;33:1121-1131.
37. Cannon, B, Hedin A, Nedergaard J. Exclusive occurrence of thermogenin antigen in brown adipose tissue. FEBS Lett 1982;150:129-132.
38. Ricquier D, Bouillaud F. Mitochondrial uncoupling proteins: from mitochondria to the regulation of energy balance. . Physiol 2000;529(Pt 1):3-10.
39. Merklin RJ. Growth and distribution of human fetal brown fat. Anat Rec 1974;178:637-645.
40. Collins S, Surwit RS. The D-adrenergic receptors and the control of adipose tissue metabolism and thermogenesis. In: Means AR, ed. Recent progress in hormone research. Bethesda, MD: Endocrine Society Press, 2001:309-328.
41. Lean ME, James WP, Jennings G, et al. Brown adipose tissue in patients with phaeochromocytoma. Int J Obes 1986;10:219-227.
42. Greenwood MR, Hirsch J. Postnatal development of adipocyte cellularity in the normal rat. . Lipid Res 1974;15:474-483.
43. Hausman GJ, Richardson RL. Cellular and vascular development in immature rat adipose tissue. . Lipid Res 1983;24:522-532.
44. Rosen ED, Walkey CJ, Puigserver P, et al. Transcriptional regulation of adipogenesis. Genes Dev 2000;14:1293-1307.
45. Surwit RS, Feinglos MN, Rodin J, et al. Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice. Metabolism 1995;44:645-651.
46. Imai T, Takakuwa R, Marchand S, et al. Peroxisome proliferator-activated receptor gamma is required in mature white and brown adipocytes for their survival in the mouse. Proc Natl Acad Sci U S A 2004;101:4543-4547.
47. Green H, Kehinde O. Sublines of mouse 3T3 cells that accumulate lipid. Cell 1974;1:113-116.
48. Morrison RF, Farmer SR. Insights into the transcriptional control of adipocyte differentiation. . Cell Biochem 1999[Suppl 32-33]:59-67.
49. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma2, a lipid-activated factor. Cell 1994;79:1147-1156.
50. Wu Z, Rosen ED, Brun R, et al. Cross-regulation of C/EBPα and PPARγ controls the transcriptional pathway of adipogenesis and insulin sensitivity. Mol Cell 1999;3:151-158.
51. Hamm JK, el Jack AK, Pilch PF, et al. Role of PPAR gamma in regulating adipocyte differentiation and insulin-responsive glucose uptake. Ann N Y Acad Sci 1999;892:134-145.
52. Dixon TM, Daniel KW, Farmer SR, et al. CAATT/enhancer binding protein-α is required for transcription of the D3AR gene during adipogenesis. Biol Chem 2001;276:722-728.
53. Tontonoz P, Hu E, Graves RA, et al. mPPAR2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994;8:1224-1234.
54. Kliewer SA, Forman BM, Blumberg B, et al. Differential expression and activation of a family of murine peroxisome proliferator-activates receptors. Proc Natl Acad Sci U S A 1994;91:7355-7359.
55. Bernlohr DA, Angus CW, Lane MD, et al. Expression of specific mRNAs during adipose differentiation: identification of an mRNA encoding a homologue of myelin P2 protein. Proc Natl Acad Sci U S A 1984;81:5468-5472.
56. Graves RA, Tontonoz P, Ross SR, et al. Identification of a potent adipocyte-specific enhancer: involvement of an NF-1-like factor. Genes Dev 1991;5:428-437.
57. Graves RA, Tontonoz P, Spiegelman BM. Analysis of a tissue-specific enhancer: ARF6 regulates adipogenic gene expression. Mol Cell Biol 1992;12: 1202-1208.
58. Rosen ED, Sarraf P, Troy AE, et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 1999;4:611-617.
59. Zhang J, Fu M, Cui T, et al. Selective disruption of PPARgamma 2 impairs the development of adipose tissue and insulin sensitivity. Proc Natl Acad Sci U S A 2004;101:10703-10708.
60. Rosen ED, Hsu CH, Wang X, et al. C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev 2002;16:22-26.
61. Ren D, Collingwood TN, Rebar EJ, et al. PPARgamma knockdown by engineered transcription factors: exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis. Genes Dev 2002;16:27-32.
62. Xu HE, Lambert MH, Montana VG, et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 1999;3:397-403.
63. Lang M, Pelkonen O. Metabolism of xenobiotics and chemical carcinogenesis. IARC Sci Publ; 1999:13-22.
64. Linhart HG, Ishimura-Oka K, DeMayo F, et al. C/EBPalpha is required for differentiation of white, but not brown, adipose tissue. Proc Natl Acad Sci U S A 2001;98:12532-12537.
65. Kubota N, Terauchi Y, Miki H, et al. PPAR gamma mediates high-fat dietinduced adipocyte hypertrophy and insulin resistance. Mol Cell 1999;4:597-609.
66. Barak Y, Nelson MC, Ong ES, et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 1999;4:585-595.
67. He W, Barak Y, Hevener A, et al. Adipose-specific peroxisome proliferatoractivated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci U S A 2003;100:15712-15717.
68. Kozak UC, Held W, Kreutter D, et al. Adrenergic regulation of the mitochondrial uncoupling protein gene in brown fat tumor cells. Mol Endocrinol 1992; 6:763-772.
69. Kozak UC, Kozak LP. Norepinephrine-dependent selection of brown adipocyte cell lines. Endocrinology 1994;134:906-913.
70. Ross SR, Choy L, Graves RA, et al. Hibernoma formation in transgenic mice and isolation of a brown adipocyte cell line expressing the uncoupling protein gene. Proc Natl Acad Sci U S A 1992;89:7561-7565.
71. Irie Y, Asano A, Canas X, et al. Immortal brown adipocytes from p53-knockout mice: differentiation and expression of uncoupling proteins. Biochem Biophys Res Commun 1999;255:221-225.
72. Rohlfs EM, Daniel KW, Premont RT, et al. Regulation of the uncoupling protein gene (Ucp) by D1, D2, D3-adrenergic subtypes in immortalized brown adipose cell lines. . Biol Chem 1995;270:10723-10732.
73. Vidal H. Gene expression in visceral and subcutaneous adipose tissues. Ann Med 2001;33:547-555.
74. Spiegelman BM, Frank M, Green H. Molecular cloning of mRNA from 3T3 adipocytes. Regulation of mRNA content for glycerophosphate dehydrogenase and other differentiation-dependent proteins during adipocyte development. . Biol Chem 1983;258:10083-10089.
75. Puigserver P, Wu Z, Park C, et al. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 1998;92:829-839.
76. Wu Z, Puigserver P, Andersson U, et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 1999;98:115-124.
77. Cao W, Daniel KW, Robidoux J, et al. p38 mitogen-activated protein kinase is the central regulator of cyclic AMP-dependent transcription of the brown fat uncoupling protein 1 gene. Mol Cell Biol 2004;24:3057-3067.
78. Kennedy GL. The role of depot fat in the hypothalamic control of food intake in the rat. Proc R Soc Lond 1953;140:579-592.
79. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998;395:763-770.
80. Coleman DL, Hummel KP. Effects of parabiosis of normal with genetically diabetic mice. Am J Physiol 1969;217:1298-1304.
81. Coleman DL. Effects of parabiosis of obese with diabetes and normal mice Diabetologia 1973;9:294-298.
82. Tartaglia LA, Dembski M, Weng X, et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 1995;83:1263-1271.
83. Lee G-H, Proenca R, Montez JM, et al. Abnormal splicing of the leptin receptor in diabetic mice. Nature 1996;379:632-635.
84. Ahima RS, Flier JS. Leptin. Annu Rev Physiol 2000;62:413-437.
85. Mueller WM, Gregoire FM, Stanhope KL, et al. Evidence that glucose metabolism regulates leptin secretion from cultured rat adipocytes. Endocrinology 1998;139:551-558.
86. Wang J, Liu R, Hawkins M, et al. A nutrient-sensing pathway regulates leptin gene expression in muscle and fat. Nature 1998;393:684-688.
87. Bluher M, Michael MD, Peroni OK, et al. Adipose tissue selective insulin receptor protects against obesity and obesity-related glucose intolerance. Dev Cell 2002;3:25-38.
88. Pelleymounter MA, Cullen MJ, Baker MB, et al. Effects of the obese gene product on body weight regulation in obob mice. Science 1995;269:540-543.
89. Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995;269:543-546.
90. Campfield LA, Smith FJ, Guisez Y, et al. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 1995;269:546-549.
91. Collins S, Kuhn CM, Petro AE, et al. Role of leptin in fat regulation. Nature 1996;380:677.
92. Sivitz WI, Fink BD, Morgan DA, et al. Sympathetic inhibition, leptin, and uncoupling protein subtype expression in normal fasting rats. Am J Physiol 1999;277:E668-677.
93. Elmquist JK, Elias CF, Saper CB. From lesions to leptin: hypothalamic control of food intake and body weight. Neuron 1999;22:221-232.
94. DeFalco J, Tomishima M, Liu H, et al. Virus-assisted mapping of neural inputs to a feeding center in the hypothalamus. Science 2001;291:2608-2613.
95. Schwartz MW. Brain pathways controlling food intake and body weight. Exp Biol Med (Maywood) 2001;226:978-981.
96. Tartaglia LA. The leptin receptor. . Biol Chem 1997;272:6093-6096.
97. Bjorbaek C, Elmquist JK, Frantz JD, et al. Identification of SOCS-3 as a potential mediator of central leptin resistance. Mol Cell 1998;1:619-625.
98. Elmquist JK. Hypothalamic pathways underlying the endocrine, autonomic, and behavioral effects of leptin. Physiol Behav 2001;74:703-708.
99. Niswender KD, Morton GJ, Stearns WH, et al. Intracellular signalling. Key enzyme in leptin-induced anorexia. Nature 2001;413:794-795.
100. Obici S, Zhang BB, Karkanias G, et al. Hypothalamic insulin signaling is required for inhibition of glucose production Nat Med 2002;8:1376-1382. 100a. Minokoshi Y, Kim YB, Peroni OD, et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002;415:339-343. 100b. Andersson U, Filipsson K, Abbott CR, et al. AMP-activated protein kinase plays a role in the control of food intake. . Biol Chem 2004;279:12005-12008. 100c. Minokoshi Y, Alquier T, Furukawa N, et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 2004;428:569-574.
101. Barsh GS, Farooqi IS, O'Rahilly S. Genetics of body-weight regulation. Nature 2000;404:644-651.
102. Ahima RS, Prabakaran D, Mantzoros C, et al. Role of leptin in the neuroendocrine response to fasting. Nature 1996;382:250-252.
103. Farooqi IS, Matarese G, Lord GM, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine dysfunction of human congenital leptin deficiency. . Clin Invest 2002;110:1093-2003.
104. Cohen P, Zhao C, Cai X, et al. Selective deletion of leptin receptor in neurons leads to obesity. . Clin Invest 2001;108:1113-1121.
105. Munzberg H, Flier JS, Bjorbaek C. Region-specific leptin resistance within the hypothalamus of diet-induced obese mice. Endocrinology 2004;Jul 22.
106. Bates SH, Stearns WH, Dundon TA, et al. STAT3 signalling is required for leptin regulation of energy balance but not reproduction. Nature 2003;421: 856-859.
107. Gao Q, Wolfgang MJ, Neschen S, et al. Disruption of neural signal transducer and activator of transcription 3 causes obesity, diabetes, infertility, and thermal dysregulation. Proc Natl Acad Sci U S A 2004;101:4661-4666.
108. Mori H, Hanada R, Hanada T, et al. Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity. Nat Med 2004; 10:739-743.
109. Howard JK, Cave BJ, Oksanen LJ, et al. Enhanced leptin sensitivity and attenuation of diet-induced obesity in mice with haploinsufficiency of Socs3. Nat Med 2004;10:734-738.
110. Ravussin E, Pratley RE, Maffei M, et al. Relatively low plasma leptin concentrations precede weight gain in Pima Indians. Nat Med 1997;3:238-240.
111. Surwit R, Petro A, Parekh P, et al. Low plasma leptin in response to dietary fat in diabetes-and obesity-prone mice. Diabetes 1997;46:1516-1520.
112. Fox CS, Esparza J, Nicolson M, et al. Is a low leptin concentration, a low resting metabolic rate, or both the expression of the "thrifty genotype"? Results from Mexican Pima Indians. Am J Clin Nutr 1998;68:1053-1057.
113. Surwit RS, Edwards CL, Murthy S, et al. Transient effects of long-term leptin supplementation in the prevention of diet-induced obesity in mice. Diabetes 2000;49:1203-1208.
114. Rosenbaum M, Murphy EM, Heymsfield SB, et al. Low dose leptin administration reverses effects of sustained weight-reduction on energy expenditure and circulating concentrations of thryoid hormoes. . Clin Endocrinol Metab 2002;87:2391-2394.
115. Chan JL, Heist K, DePaoli AM, et al. The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. . Clin Invest 2003;111:1409-1421.
116. Laughlin GA, Yen SS. Hypoleptinemia in women athletes: absence of a diurnal rhythm with amenorrhea. . Clin Endocrinol Metab 1997;82:318-321.
117. Kahn BB, Flier JS. Obesity and insulin resistance. . Clin Invest 2000;106: 473-481.
118. Fielding BA, Frayn KN. Lipoprotein lipase and the disposition of dietary fatty acids. Br J Nutr 1998;80:495-502.
119. Paradis S, Ruvkun G. Caenorhabditis elegans Akt/PKB transduces insulin receptor-like signals from AGE-1 PI3 kinase to the DAF-16 transcription factor. Genes Dev 1998;12:2488-2498.
120. White MF. The IRS-signaling system: a network of docking proteins that mediate insulin and cytokine action. Recent Prog Horm Res 1998;53:119-138.
121. Staubs PA, Nelson JG, Reichart DR, et al. Platelet-derived growth factor inhibits insulin stimulation of insulin receptor substrate-1-associated phosphatidylinositol 3-kinase in 3T3-L1 adipocytes without affecting glucose transport. . Biol Chem 1998;273:25139-25147.
122. Czech MP, Corvera S. Signaling mechanisms that regulate glucose transport. . Biol Chem 1999;274:1865-1868.
123. Wang Q, Somwar R, Bilan PJ, et al. Protein kinase B/Akt participates in GLUT4 translocation by insulin in L6 myoblasts. Mol Cell Biol 1999;19:4008-4018.
124. Kitamura T, Ogawa W, Sakaue H, et al. Requirement for activation of the serine-threonine kinase Akt (protein kinase B) in insulin stimulation of protein synthesis but not of glucose transport. Mol Cell Biol 1998;18:3708-3717.
125. Kotani K, Ogawa W, Matsumoto M, et al. Requirement of atypical protein kinase C lambda for insulin stimulation of glucose uptake but not for Akt activation in 3T3-L1 adipocytes. Mol Cell Biol 1998;18:6971-6982.
126. Kitamura T, Kitamura Y, Kuroda S, et al. Insulin-induced phosphorylation and activation of cyclic nucleotide phosphodiesterase 3B by the serine-threonine kinase Akt. Mol Cell Biol 1999;19:6286-6296.
127. Kim J, Sarraf P, Wright M, et al. Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1. . Clin Invest 1998;101:1-9.
128. Shimomura I, Bashmakov Y, Horton JD. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. . Biol Chem 1999;274:30028-30032.
129. Foretz M, Guichard C, Ferre P, et al. Sterol regulatory element binding protein-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes. Proc Natl Acad Sci U S A 1999;96: 12737-12742.
130. Kops GJ, Burgering BM. Forkhead transcription factors: new insights into protein kinase B (c-Akt) signaling. . Mol Med 1999;77:656-665.
131. Puigserver P, Rhee J, Donovan J, et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 2003;423:550-555.
132. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev 1995;75:473-486.
133. Bergman RN, Van Citters GW, Mittelman SD, et al. Central role of the adipocyte in the metabolic syndrome. . Invest Med 2001;49:119-126.
134. Martin T, Collins S, Surwit RS. The C57BL/6J mouse as a model of insulin resistance and hypertension. In: Hansen BC, ed. Lessons from animal diabetes. Madras: Newgen Imaging Systems, 2002:73-86.
135. Rondinone CM, Wang LM, Lonnroth P, et al. Insulin receptor substrate (IRS) 1 is reduced and IRS-2 is the main docking protein for phosphatidylinositol 3-kinase in adipocytes from subjects with non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A 1997;94;4171-4175.
136. Goldstein B, Bittner-Kowalczyk J, White A, et al. Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein-tyrosine phosphatase 1B: possible facilitation by the formation of a ternary complex with the Grb2 adaptor protein. . Biol Chem 2000;275:4283-4289.
137. Zabolotny JM, Kim YB, Peroni OD, et al. Overexpression of the LAR (leukocyte antigen-related) protein-tyrosine phosphatase in muscle causes insulin resistance. Proc Natl Acad Sci U S A 2001;98:5187-5192.
138. Zabolotny JM, Haj FG, Kim YB, et al. Transgenic overexpression of proteintyrosine phosphatase 1B in muscle causes insulin resistance, but overexpression with leukocyte antigen-related phosphatase does not additively impair insulin action. . Biol Chem 2004;279:24844-24851.
139. Elchebly M, Payette P, Michaliszyn E, et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 1999;283:1544-1548.
140. Ren JM, Li PM, Zhang WR, et al. Transgenic mice deficient in the LAR protein-tyrosine phosphatase exhibit profound defects in glucose homeostasis. Diabetes 1998;47:493-497.
141. Cheng A, Uetani N, Simoncic PD, et al. Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B. Dev Cell 2002;2:497-503.
142. Zabolotny JM, Bence-Hanulec JM, Stricker-Krongrad KK, et al. PTP1B regulates leptin signal transduction in vivo. Dev Cell 2002;2:489-495.
143. Kraegen EW, James DE, Jenkins AB, et al. Dose-response curves for in vivo insulin sensitivity in individual tissues in rats. Am J Physiol 1985;248:E353-362.
144. Shepherd PR, Gnudi L, Tozzi E, et al. Adipose tissue hyperplasia and enhanced glucose disposal in transgenic mice overexpressing GLUT4 selectively in adipose tissue. . Biol Chem 1993;268:22243-22246.
145. Tozzo E, Gnudi L, Kahn BB. Amelioration of insulin resistance in streptozocin diabetic mice by transgenic overexpression of GLUT4 driven by an adipose-specific promoter. Endocrinology 1997;138:1604-1611.
146. Abel ED, Peroni O, Kim JK, et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 2001;409:729-733.
147. Colditz GA, Willett WC, Stampfer MJ, et al. Weight as a risk factor for clinical diabetes in women. Am J Epidemiol 1990;132:501-513.
148. Bjorntorp P. Body fat distribution, insulin resistance, and metabolic diseases. Nutrition 1997;13:795-803.
149. Okosun IS. Racial differences in rates of type 2 diabetes in American women: how much is due to differences in overall adiposity? Ethn Health 2001;6: 27-34.
150. Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev 1994;74:761-811.
151. Bergman RN, Ader M. Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab 2000;11:351-356.
152. Patti M-E, Kahn CR. Lessons from transgenic and knockout animals about noninsulin-dependent diabetes mellitus. Trends Endocrinol Metab 1996;7: 311-319.
153. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Diabetes 1995;44:863-870.
154. Griffin ME, Marcucci MJ, Cline GW, et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 1999;48:1270-1274.
155. Zierath JR, Houseknecht KL, Gnudi L, et al. High-fat feeding impairs insulinstimulated GLUT4 recruitment via an early insulin-signaling defect. Diabetes 1997;46:215-223.
156. Borkman M, Storlien LH, Pan DA, et al. The relation between insulin sensitivity and the fatty-acid composition of skeletal-muscle phospholipids. . Engl J Med 1993;328:238-244.
157. Shimabukuro M, Higa M, Zhou YT, et al. Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats. Role of serine palmitoyltransferase overexpression. . Biol Chem 1998;273:32487-32490.
158. Shimomura I, Hammer RE, Ikemoto S, et al. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999;401:73-76.
159. Gavrilova O, Marcus-Samuels B, Graham D, et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. . Clin Invest 2000;105:271-278.
160. Ogawa Y, Masuzaki H, Hosoda K, et al. Increased glucose metabolism and insulin sensitivity in transgenic skinny mice overexpressing leptin. Diabetes 1999;48:1822-1829.
161. Savage DB, O'Reilly S. Leptin: a novel therapeutic role in lipodystrophy. . Clin Invest 2002;109:1285-1286.
162. Petersen KF, Oral EA, Dufour S, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. . Clin Invest 2002;109: 1345-1350.
163. Oral EA, Simha V, Ruiz E, et al. Leptin-replacement therapy for lipodystrophy. . Engl J Med 2002;346:570-578.
164. Minokoshi Y, Kim YB, Peroni OD, et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002;415:339-343.
165. Salway J. Metabolism at a glance, 2nd ed. Blackwell Science: Oxford, 1999.
166. Galitzky J, Reverte M, Portill M, et al. Coexistence of beta 1-, beta 2-, and beta 3-adrenoceptors in dog fat cells and their differential activation by catecholamines. Am J Physiol 1993;264:E403-E412.
167. Collins S, Daniel KW, Rohlfs EM, et al. Impaired expression and functional activity of the beta 3-and beta 1-adrenergic receptors in adipose tissue of congenitally obese (C57BL/6J ob/ob) mice. Mol Endocrinol 1994;8:516-527.
168. Atgie C, D'Allaire F, Bukowiecki LJ. Role of beta1-and beta3-adrenoceptors in the regulation of lipolysis and thermogenesis in rat brown adipocytes. Am J Physiol 1997;273:C1136-C1142.
169. Rohrer DK. Physiological consequences of D-adrenergic receptor disruption. . Mol Med 1999;76:764-772.
170. Bachman ES, Dhillon H, Zhang CY, et al. BetaAR signaling is required for diet-induced thermogenesis and obesity resistance. Science 2002;297:843-845.
171. Jimenez M, Leger B, Canola K. et al. Beta(1)/beta(2)/beta(3)-adrenoceptor knockout mice are obese and cold-sensitive but have normal lipolytic responses to fasting. FEBS Lett 2002;530:37-40.
172. Soeder KS, Snedden SK, Cao W, et al. The D3-adrenergic receptor activates mitogen-activated protein kinase in adipocytes through a Gi-dependent mechanism. . Biol Chem 1999;274:12017-12022.
173. Cao W, Medvedev AV, Daniel KW, et al. D-Adrenergic activation of p38 MAP kinase in adipocytes: cAMP induction of the uncoupling protein-1 (UCP1) gene requires p38 MAP kinase. . Biol Chem 2001;276:27077-27082.
174. Moule SK, Denton RM. The activation of p38 MAPK by the beta-adrenergic agonist isoproterenol in rat epididymal fat cells. FEBS Lett 1998;439:287-290.
175. Greenberg AS, Shen WJ, Muliro K, et al. Stimulation of lipolysis and hormone-sensitive lipase via the extracellular signal-regulated kinase pathway. . Biol Chem 2001;276:45456-45461.
176. Robidoux JR, Cao W, Cyr M, et al. Protein kinase A and ERK1/2 mitogenactivated protein kinases work in concert to mediate the D-adrenergic stimulation of lipolysis (submitted for publication).
177. Lafontan M, Berlan M. Fat cell 2-adrenoceptors: the regulation of fat cell function and lipolysis. Endocr Rev 1995;16:716-738.
178. Gettys TW, Harkness PJ, Watson PM. The D3-adrenergic receptor inhibits insulin-stimulated leptin secretion from isolated rat adipocytes. Endocrinology 1996;137:4054-4057.
179. Donahoo WT, Jensen DR, Yost TJ, et al. Isoproterenol and somatostatin decrease plasma leptin in humans: a novel mechanism regulating leptin secretion. . Clin Endocrinol Metab 1997;82:4139-4143.
180. Scriba D, Aprath-Husmann I, Blum WF, et al. Catecholamines suppress leptin release from in vitro differentiated subcutaneous human adipocytes in primary culture via beta1-and beta2-adrenergic receptors. Eur J Endocrinol 2000;143:439-445.
181. Jimenez M, Leger B, Canola K, et al. beta(1)/beta(2)/beta(3)-adrenergic receptor knockout mice are obese and cold-sensitive but have normal lipolytic responses to fasting. FEBS Lett 2002;530:37.
182. Champigny O, Ricquier D, Blondel O, et al. D3-Adrenergic receptor stimulation restores message and expression of brown-fat mitochondrial uncoupling protein in adult dogs. Proc Natl Acad Sci U S A 1991;88:10774-10777.
183. Himms-Hagen J, Cui J, Danforth E Jr, et al. Effect of CL-316,243, a thermogenic D3-agonist, on energy balance and brown and white adipose tissues in rats. Am J Physiol 1994;266:R1371-R1382.
184. Collins S, Daniel KW, Petro AE, et al. Strain-specific response to D3-adrenergic receptor agonist treatment of diet-induced obesity in mice. Endocrinology 1997;138:405-413.
185. Ghorbani M, Himms-Hagen J. Appearance of brown adipocytes in white adipose tissue during CL 316,243-induced reversal of obesity and diabetes in Zucker fa/fa rats. Int J Obes Relat Metab Disord 1997;21:465-475.
186. Fisher MH, Amend AM, Bach TJ, et al. A selective human beta3 adrenergic receptor agonist increases metabolic rate in rhesus monkeys. . Clin Invest 1998;101:2387-2393.
187. Sasaki N, Uchida E, Niiyama M, et al. Anti-obesity effects of selective agonists to the D3-adrenergic receptor in dogs. II. Recruitment of thermogenic brown adipocytes and reduction of adiposity after chronic treatment with a D3-adrenergic agonist. . Vet Med Sci 1998;60:465-469.
188. Ghorbani M, Claus TH, Himms-Hagen J. Hypertrophy of brown adipocytes in brown and white adipose tissues and reversal of diet-induced obesity in rats treated with a beta3-adrenoceptor agonist. Biochem Pharmacol 1997;54: 121-131.
189. de Souza CJ, Hirshman MF, Horton ES. CL-316,243, a beta3-specific adrenoceptor agonist, enhances insulin-stimulated glucose disposal in nonobese rats. Diabetes 1997;46:1257-1263.
190. Weyer C, Tataranni PA, Snitker S, et al. Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans. Diabetes 1998;47:1555-1561.
191. Granneman JG, Burnazi M, Zhu Z, et al. White adipose tissue contributes to UCP1-independent thermogenesis. Am J Physiol Endocrinol Metab 2003;285: E1230-1236.
192. Wilson-Fritch L, Burkart A, Bell G, et al. Mitochondrial biogenesis and remodeling during adipogenesis and in response to the insulin sensitizer rosiglitazone. Mol Cell Biol 2003;23:1085-1094.
193. Simpson ER, Zhao Y, Agarwal VR, et al. Aromatase expression in health and disease. Recent Prog Horm Res 1997;52:185-213.
194. Deslypere JP, Verdonck L, Vermeulen A. Fat tissue: a steroid reservoir and site of steroid metabolism. . Clin Endocrinol Metab 1985;61:564-570.
195. Jensen MD. Androgen effect on body composition and fat metabolism. Mayo Clin Proc 2000;75[Suppl]:S65-68.
196. Tchernof A, Despres JP. Sex steroid hormones, sex hormone-binding globulin, and obesity in men and women. Horm Metab Res 2000;32:526-536.
197. Seckl JR, Walker BR. Minireview: 11beta-hydroxysteroid dehydrogenase type 1-a tissue-specific amplifier of glucocorticoid action. Endocrinology 2001; 142:1371-1376.
198. Stewart PM. Cortisol, hypertension and obesity: the role of 11 beta-hydroxysteroid dehydrogenase. . R Coll Physicians Lond 1998;32:154-159.
199. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001;294:2166-2170.
200. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect "Cushing's disease of the omentum"? Lancet 1997;349:1210-1213.
201. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001;294:2166-2170.
202. Morton NM, Paterson JM, Masuzaki H, et al. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11D-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 2004;53:931-938.
203. Morton NM, Holmes MC, Fievet C, et al. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11D-hydroxysteroid dehydrogenase type 1 null mice. . Biol Chem 2004;276:41293-41300.
204. Beutler B, Cerami A. The biology of cachectin/TNF-a primary mediator of the host response. Annu Rev Immunol 1989;7:625-655.
205. Lang CH, Dobrescu C, Bagby GJ. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 1992;130:43-52.
206. Hotamisligil G, Shargill N, Spiegelman B. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87-91.
207. Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. Clin Invest 1995;95:2409-2415.
208. Hotamisligil GS. The role of TNFalpha and TNF receptors in obesity and insulin resistance. . Intern Med 1999;245:621-625.
209. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. . Clin Endocrinol Metab 1998;83:847-850.
210. Yudkin JS, Stehouwer CD, Emeis JJ, et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19:972-978.
211. Shimomura I, Funahashi T, Takahashi M, et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996;2:800-803.
212. Samad F, Loskutoff DJ. Hemostatic gene expression and vascular disease in obesity: insights from studies of genetically obese mice. Thromb Haemost 1999;82:742-747.
213. Funahashi T, Nakamura T, Shimomura I, et al. Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Intern Med 1999;38: 202-206.
214. Loskutoff DJ, Fujisawa K, Samad F. The fat mouse. Apowerful genetic model to study hemostatic gene expression in obesity/NIDDM. Ann N Y Acad Sci 2000;902:272-281.
215. Chandra RK. Nutrition and the immune system: an introduction. Am J Clin Nutr 1997;66:460S-463S.
216. Faggioni R, Feingold KR, Grunfeld C. Leptin regulation of the immune response and the immunodeficiency of malnutrition. FASEB J 2001;15: 2565-2571.
217. Sisson JG, West RJ, Fallow J, et al. The complement abnormalities of lipodystrophy. . Engl J Med 1976;294:461-465.
218. Cook KS, Min HY, Johnson D, et al. Adipsin: a circulating serine protease homolog secreted by adipose tissue and sciatic nerve. Science 1987;237: 402-405.
219. Choy LN, Rosen BS, Spiegelman BM. Adipsin and an endogenous pathway of complement from adipose cells. . Biol Chem 1992;267:12736-12741.
220. Flier JS, Cook KS, Usher P, et al. Severely impaired adipsin expression in genetic and acquired obesity. Science 1987;237:405-408.
221. White RT, Damm D, Hancock N, et al. Human adipsin is identical to complement factor D and is expressed at high levels in adipose tissue. . Biol Chem 1992;267:9210-9213.
222. Napolitano A, Lowell BB, Damm D, et al. Concentrations of adipsin in blood and rates of adipsin secretion by adipose tissue in humans with normal, elevated and diminished adipose tissue mass. Int J Obes Relat Metab Disord 1994; 18:213-218.
223. Esterbauer H, Krempler F, Oberkofler H, et al. The complement system: a pathway linking host defence and adipocyte biology. Eur J Clin Invest 1999; 29:653-656.
224. Coleman DL. Inherited obesity-diabetes syndromes in the mouse. In: Mammalian genetics and cancer: the Jackson Laboratory Fiftieth Anniversary Symposium. New York: Alan R Liss, 1979:145-158.
225. Baldo A, Sniderman AD, St-Luce S, et al. The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis. . Clin Invest 1993;92:1543-1547.
226. Murray I, Sniderman AD, Havel PJ, et al. Acylation stimulating protein (ASP) deficiency alters postprandial and adipose tissue metabolism in male mice. . Biol Chem 1999;274:36219-36225.
227. Scherer P, Williams S, Fogliano M, et al. Anovel serum protein similar to C1q, produced exclusively in adipocytes. . Biol Chem 1995;270:26746-26749.
228. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. . Biol Chem 1996;271:10697-10703.
229. Nakano Y, Tobe T, Choi-Miura NH, et al. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. . Biochem (Tokyo) 1996;120:803-812.
230. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79-83.
231. Maeda K, Okubo K, Shimomura I, et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose most abundant gene transcript 1). Biochem Biophys Res Commun 1996;221:286-289.
232. Shapiro L, Scherer PE. The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol 1998;8:335-338.
233. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002;13:84-89.
234. Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 2001;98:2005-2010.
235. Combs TP, Berg AH, Obici S, et al. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. . Clin Invest 2001;108:1875-1881.
236. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288-1295.
237. Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. . Biol Chem 2002;277:25863-25866.
238. Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacing adiponectin/ACRP30. Nat Med 2002;8:731-737.
239. Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. . Clin Endocrinol Metab 2001;86:3815-3819.
240. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. . Clin Endocrinol Metab 2001;86:1930-1935.
241. Hotta K, Funahashi T, Bodkin NL, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001;50:1126-1133.
242. Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001;103: 1057-1063.
243. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000;102:1296-1301.
244. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595-1599.
245. Pajvani UB, Hawkins M, Combs TP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. . Biol Chem 2004;279:12152-12162.
246. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003;423:762-769.
247. Hug C, Wang J, Ahmad NS, et al. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci U S A 2004;101:10308-10313.
248. Cassis LA, Saye J, Peach MJ. Location and regulation of rat angiotensinogen messenger RNA. Hypertension 1988;11:591-596.
249. Engeli S, Gorzelniak K, Kreutz R, et al. Co-expression of renin-angiotensin system genes in human adipose tissue. . Hypertens 1999;17:555-560.
250. Karlsson C, Lindell K, Ottosson M, et al. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin. II. . Clin Endocrinol Metab 1998;83:3925-3929.
251. Frederich RC Jr, Kahn BB, Peach MJ, et al. Tissue-specific nutritional regulation of angiotensinogen in adipose tissue. Hypertension 1992;19:339-344.
252. Saye JA, Cassis LA, Sturgill TW, et al. Angiotensinogen gene expression in 3T3-L1 cells. Am J Physiol 1989;256:C448-451.
253. Saye J, Lynch KR, Peach MJ. Changes in angiotensinogen messenger RNA in differentiating 3T3-F442A adipocytes. Hypertension 1990;15:867-871.
254. Safonova I, Aubert J, Negrel R, et al. Regulation by fatty acids of angiotensinogen gene expression in preadipose cells. Biochem J 1997;322: 235-239.
255. Massiera F, Seydoux J, Geloen A, et al. Angiotensinogen-deficient mice exhibit impairment of diet-induced weight gain with alteration in adipose tissue development and increased locomotor activity. Endocrinology 2001;142:5220-5225.
256. Massiera F, Bloch-Faure M, Ceiler D, et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 2001;15:2727-2729.
257. Masuzaki H, Yamamoto H, Kenyon CJ, et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in lmice. . Clin Invest 2003;112:83-90.
258. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307-312.
259. Holcomb IN, Kabakoff RC, Chan B, et al. FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J 2000;19:4046-4055.
260. Steppan CM, Brown EJ, Wright CM, et al. A family of tissue-specific resistinlike molecules. Proc Natl Acad Sci U S A 2001;98:502-506.
261. Kim KH, Lee K, Moon YS, et al. A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. . Biol Chem 2001;276: 11252-11256.
262. Way JM, Gorgun CZ, Tong Q, et al. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferatoractivated receptor gamma agonists. . Biol Chem 2001;276:25651-25653.
263. McTernan PG, McTernan CL, Chetty R, et al. Increased resistin gene and protein expression in human abdominal adipose tissue. . Clin Endocrinol Metab 2002;87:2407-2410.
264. Savage DB, Sewter CP, Klenk ES, et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001;50:2199-2202.
265. Patel SD, Rajala MW, Rossetti L, et al. Disulfide-dependent multimeric assembly of resistin family hormones. Science 2004;304:1154-1158.
266. Satoh H, Nguyen MT, Miles PD, et al. Adenovirus-mediated chronic "hyperresistinemia" leads to in vivo insuln resistance in normal rats. . Clin Invest 2004;114:224-231.
267. Banerjee RR, Rangwala SM, Shapiro JS, et al. Regulation of fasted blood glucose by resistin. Science 2004;303:1195-1198.
268. Muse ED, Obici S, Bhanot S, et al. Role of resistin in diet-induced hepatic insulin resistance. . Clin Invest 2004;114:232-239.
269. Rajala MW, Qi Y, Patel HR, et al. Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes 2004;53:1671-1679.
270. Savage DB, Sewter CP, Klenk ES, et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001;50:2199-2202.
271. Steppan CM, Lazar MA. The current biology of resistin. . Intern Med 2004; 255:439-447.